At its meeting on 09 January 2023, the Transparency Council adopted Opinion No. 6/2023 on the evaluation of the medicine Verzenios (abemaciclib) under the drug programme “Treatment of patients with breast cancer (ICD-10: C50)”.
At its meeting on 09 January 2023, the Transparency Council adopted Opinion No. 6/2023 on the evaluation of the medicine Verzenios (abemaciclib) under the drug programme “Treatment of patients with breast cancer (ICD-10: C50)”.